Factor VIII Activity Test in Karachi at Dr. Essa Lab

Factor VIII at Dr. Essa Lab

The Factor VIII test at Dr. Essa Lab is a highly specialized coagulation assay designed to measure the activity and functional capacity of Factor VIII, an essential blood-clotting protein. Also known as antihemophilic factor, Factor VIII plays a critical role in the intrinsic pathway of the coagulation cascade. When a blood vessel is injured, a complex series of chemical reactions occurs to form a stable blood clot and prevent excessive bleeding. Factor VIII acts as a vital cofactor for activated Factor IX, assembling into the tenase complex on phospholipid surfaces to activate Factor X. A deficiency, malfunction, or elevation of this protein can lead to severe, life-threatening hematological conditions. Dr. Essa Laboratory and Diagnostic Centre, a pioneer in diagnostic services in Karachi, Pakistan, utilizes advanced automated coagulation analyzers to deliver precise and clinically reliable Factor VIII measurements for patients requiring comprehensive hematological evaluations.

Understanding the clinical importance of Factor VIII is essential for diagnosing inherited and acquired bleeding disorders. The most notable condition associated with a deficiency of this protein is Hemophilia A, an X-linked recessive genetic disorder that primarily affects males. Additionally, Factor VIII is closely linked to Von Willebrand Factor, a carrier protein that stabilizes Factor VIII in circulation and protects it from rapid proteolytic degradation. Consequently, patients with Von Willebrand Disease often exhibit secondary deficiencies in Factor VIII activity. Conversely, abnormally high levels of Factor VIII are recognized as a significant risk factor for venous thromboembolism, including deep vein thrombosis and pulmonary embolism. By providing accurate quantitative assessments, Dr. Essa Lab assists hematologists, pediatricians, and surgeons in making informed clinical decisions, planning surgical interventions, and monitoring therapeutic replacement therapies.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is crucial to ensure the accuracy of the Factor VIII test, as various physiological and pharmacological factors can transiently alter clotting factor levels. Patients must adhere to the following guidelines prior to undergoing the venipuncture:

• Avoid Strenuous Exercise: Physical exertion, intense workouts, and severe stress can cause a transient, physiological rise in Factor VIII levels due to the release of adrenaline. Patients should avoid vigorous exercise for at least 24 hours before the test.
• Medication Disclosure: It is imperative to inform the healthcare provider and laboratory staff of all medications, particularly anticoagulants such as heparin, warfarin, direct oral anticoagulants, or aspirin, as these can interfere with coagulation assays.
• Fasting Requirements: Routine fasting is generally not required for a Factor VIII activity test. However, patients should follow any specific dietary instructions provided by their referring physician.
• Timing of Therapy: If the patient is undergoing Factor VIII replacement therapy, the blood sample should be drawn at specific times, such as trough or peak levels, as directed by the treating hematologist to monitor therapeutic efficacy accurately.
• Rest Before the Draw: Patients are advised to sit quietly and rest for 15 to 20 minutes immediately before the blood collection to minimize stress-induced fluctuations in clotting factors.

During the Procedure

The Factor VIII test is performed on a standard venous blood sample. The procedure is conducted by highly trained phlebotomists at Dr. Essa Lab, ensuring minimal discomfort and adherence to strict pre-analytical protocols:

• Patient Positioning: The patient is seated comfortably, and the phlebotomist identifies a suitable vein, typically in the antecubital fossa of the arm.
• Aseptic Technique: The skin over the selected vein is thoroughly cleansed with an antiseptic solution to prevent contamination.
• Venipuncture and Sample Collection: A sterile needle is inserted into the vein, and blood is drawn directly into a light blue-top tube containing a precise concentration of buffered sodium citrate. This anticoagulant preserves the coagulation factors by chelating calcium.
• Critical Draw Volume: The tube must be filled completely to the designated fill line to maintain the exact 9:1 ratio of blood to anticoagulant. An incorrect ratio can significantly alter clotting times and produce inaccurate results.
• Post-Collection Care: After removing the needle, gentle pressure is applied to the puncture site with a sterile gauze pad, followed by the application of a bandage. The tube is gently inverted several times to mix the blood with the citrate stabilizer.
• Processing and Safety: The sample is promptly transported to the hematology laboratory, where it undergoes rapid centrifugation to obtain platelet-poor plasma, which is then analyzed using advanced automated coagulometers. The entire venipuncture process takes less than five minutes.

When is a Factor VIII Performed?

Diagnosing Hemophilia A

Physicians request a Factor VIII test when a patient presents with symptoms suggestive of Hemophilia A, an inherited bleeding disorder. Common clinical manifestations include spontaneous bleeding into joints, muscle hemorrhages, prolonged bleeding after minor cuts, easy bruising, and frequent nosebleeds. The test is essential to confirm the diagnosis, differentiate Hemophilia A from other bleeding disorders, and classify its severity as mild, moderate, or severe based on the percentage of functional Factor VIII activity present in the plasma.

Evaluating Von Willebrand Disease

Because Von Willebrand Factor serves as the essential carrier and stabilizer for Factor VIII in the bloodstream, any quantitative or qualitative defect in Von Willebrand Factor can result in a secondary decrease in Factor VIII levels. A Factor VIII assay is performed alongside Von Willebrand Factor antigen and activity tests to evaluate patients suspected of having Von Willebrand Disease, particularly when they present with mucosal bleeding, heavy menstrual periods, or excessive bleeding after dental and surgical procedures.

Investigating Unexplained Prolonged aPTT

An Activated Partial Thromboplastin Time is a routine screening test that measures the overall integrity of the intrinsic and common coagulation pathways. If a routine pre-operative screen or diagnostic workup reveals an unexplained prolongation of the aPTT, a Factor VIII activity test is indicated as part of a reflex testing panel. This helps determine if the prolonged clotting time is due to a specific deficiency of Factor VIII or the presence of a specific coagulation inhibitor.

Assessing Recurrent Venous Thromboembolism

While low levels of Factor VIII cause bleeding, persistently elevated levels of Factor VIII are a well-documented risk factor for thrombosis. Physicians order this test for patients who have experienced recurrent, unexplained deep vein thrombosis or pulmonary embolism, especially in the absence of traditional risk factors. Identifying elevated Factor VIII levels helps clinicians assess the patient’s long-term thrombotic risk and determine the appropriate duration of anticoagulant therapy.

Monitoring Therapeutic Factor VIII Replacement

For patients with known Hemophilia A who are receiving prophylactic or on-demand Factor VIII concentrate infusions, regular monitoring is vital. The Factor VIII test is performed to assess the pharmacokinetics of the infused factor, ensure therapeutic levels are achieved to prevent or treat bleeding episodes, and screen for the development of neutralizing antibodies that can render the replacement therapy ineffective.

What Does a Factor VIII Detect?

The quantitative Factor VIII activity assay is highly sensitive and capable of detecting a wide range of physiological, pathological, and therapeutic states. Specifically, this diagnostic test can detect:

• Severe Hemophilia A characterized by Factor VIII activity levels of less than 1 percent of normal.
• Moderate Hemophilia A indicated by functional activity levels ranging between 1 percent and 5 percent.
• Mild Hemophilia A represented by activity levels between 5 percent and 40 percent.
• Type 1 Von Willebrand Disease, which often presents with moderately reduced Factor VIII levels.
• Type 2 Von Willebrand Disease, where dysfunctional carrier proteins lead to secondary Factor VIII reduction.
• Type 3 Von Willebrand Disease, a severe form causing extremely low levels of both Von Willebrand Factor and Factor VIII.
• Acquired Hemophilia A, a rare autoimmune condition where autoantibodies neutralize endogenous Factor VIII.
• The presence of specific Factor VIII inhibitors developed after replacement therapy.
• Lupus anticoagulants or non-specific inhibitors that interfere with phospholipid-dependent coagulation assays.
• Physiological elevations associated with the third trimester of pregnancy.
• Estrogen-induced elevations resulting from oral contraceptive use or hormone replacement therapy.
• Acute phase reactant responses, where physical trauma, surgery, or acute infection transiently elevates levels.
• Chronic inflammatory conditions, such as rheumatoid arthritis or inflammatory bowel disease, causing persistent elevations.
• Advanced liver disease or cirrhosis, which can alter the synthesis and clearance of various coagulation factors.
• Disseminated Intravascular Coagulation, where rapid consumption of clotting factors leads to depleted Factor VIII.
• Hyperthyroidism, which can metabolically upregulate the production of Factor VIII.
• Malignancy-associated hypercoagulability, where tumor cells stimulate the production of clotting factors.
• Increased risk for primary or recurrent deep vein thrombosis in patients with levels exceeding 150 percent.
• Elevated risk for pulmonary embolism secondary to persistent hypercoagulability.
• Carrier status in females carrying the Hemophilia A genetic mutation, who may display borderline-low levels.
• The therapeutic efficacy and recovery rate of recombinant or plasma-derived Factor VIII concentrates.
• Post-operative stress-induced hypercoagulability, helping guide thromboprophylaxis strategies.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is committed to providing rapid and highly accurate diagnostic results to facilitate timely clinical interventions. The Factor VIII activity test requires specialized processing and automated coagulation analysis. Typically, the reports are verified by a consultant hematologist and made available within 24 to 48 hours of sample collection. Patients are notified via an automated SMS alert once their results are finalized. Reports can be easily accessed and downloaded online through the official Dr. Essa Lab web portal or mobile application. Alternatively, physical copies of the reports can be collected from any of the convenient diagnostic branches located across Karachi and other major cities.

Factor VIII Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Factor VIII Functional Activity	50% to 150% (0.50 to 1.50 IU/mL)	Decreased (less than 50%) or Elevated (greater than 150%) activity levels
Severe Deficiency State	Not applicable	Less than 1% activity (indicative of Severe Hemophilia A)
Moderate Deficiency State	Not applicable	1% to 5% activity (indicative of Moderate Hemophilia A)
Mild Deficiency State	Not applicable	5% to 40% activity (indicative of Mild Hemophilia A or carrier state)
Co-factor Association	Normal parallel Von Willebrand Factor levels	Concomitantly low Factor VIII and low Von Willebrand Factor
Inhibitor Presence Screen	No neutralizing antibodies detected	Presence of specific Factor VIII autoantibodies or acquired inhibitors
Hypercoagulable State Risk	Normal baseline risk (levels less than 150%)	Levels greater than 150% (indicates high risk for venous thromboembolism)
Consumptive Coagulopathy	Stable factor levels during acute illness	Markedly decreased levels due to consumption in active Disseminated Intravascular Coagulation

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Factor VIII?

• Experienced Healthcare Professionals: Dr. Essa Lab features a team of highly qualified consultant pathologists, hematologists, and technologists specializing in complex coagulation disorders.
• Patient-Focused Care: The laboratory prioritizes patient comfort, safety, and clear communication throughout the testing process.
• Quality Diagnostic Services: Utilizing state-of-the-art automated coagulation systems ensures high precision, reproducibility, and accuracy in Factor VIII measurements.
• Professional Reporting: All coagulation profiles and specialized factor assays undergo rigorous multi-level verification before final release.
• Modern Diagnostic Approach: Dr. Essa Lab integrates advanced laboratory information management systems to track samples and prevent pre-analytical errors.
• Comfortable Environment: Every collection center is designed to provide a clean, hygienic, and welcoming atmosphere for patients of all ages.
• Convenient Location: With an extensive network of branches across Karachi, patients can easily find a collection center near their home or workplace.
• Commitment to Accurate Diagnosis: Adherence to international quality control standards ensures that every test result is reliable and clinically actionable.